These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28596919)

  • 1. Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.
    Yamaguchi M; Nakao S; Arima M; Wada I; Kaizu Y; Hao F; Yoshida S; Sonoda KH
    J Ophthalmol; 2017; 2017():8543592. PubMed ID: 28596919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target].
    Kita T
    Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):927-34. PubMed ID: 21141072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.
    Kita T; Hata Y; Arita R; Kawahara S; Miura M; Nakao S; Mochizuki Y; Enaida H; Goto Y; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
    Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17504-9. PubMed ID: 18952846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
    Abbhi V; Piplani P
    Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
    Zhou H; Li YJ
    Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
    Shimokawa H; Satoh K
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.
    Moura-Coelho N; Tavares Ferreira J; Bruxelas CP; Dutra-Medeiros M; Cunha JP; Pinto Proença R
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1101-1117. PubMed ID: 30843105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho-Associated Coiled-Coil Kinase (ROCK) in Molecular Regulation of Angiogenesis.
    Liu J; Wada Y; Katsura M; Tozawa H; Erwin N; Kapron CM; Bao G; Liu J
    Theranostics; 2018; 8(21):6053-6069. PubMed ID: 30613282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.
    Kubo T; Yamaguchi A; Iwata N; Yamashita T
    Ther Clin Risk Manag; 2008 Jun; 4(3):605-15. PubMed ID: 18827856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
    Feng Y; LoGrasso PV; Defert O; Li R
    J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.
    Challa P; Arnold JJ
    Expert Opin Investig Drugs; 2014 Jan; 23(1):81-95. PubMed ID: 24094075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Rho-kinase inhibitors for cardiovascular medicine.
    Shimokawa H; Rashid M
    Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rho-kinase inhibitors in the management of glaucoma.
    Berrino E; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
    [No Abstract]   [Full Text] [Related]  

  • 14. AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.
    Hollanders K; Hove IV; Sergeys J; Bergen TV; Lefevere E; Kindt N; Castermans K; Vandewalle E; van Pelt J; Moons L; Stalmans I
    Curr Eye Res; 2017 Feb; 42(2):260-272. PubMed ID: 27399806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.
    Moshirfar M; Parker L; Birdsong OC; Ronquillo YC; Hofstedt D; Shah TJ; Gomez AT; Hoopes PCS
    Med Hypothesis Discov Innov Ophthalmol; 2018; 7(3):101-111. PubMed ID: 30386798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rho kinase inhibitors: a patent review (2014 - 2016).
    Defert O; Boland S
    Expert Opin Ther Pat; 2017 Apr; 27(4):507-515. PubMed ID: 28048944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability.
    Sun H; Breslin JW; Zhu J; Yuan SY; Wu MH
    Microcirculation; 2006; 13(3):237-47. PubMed ID: 16627366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
    Knipe RS; Tager AM; Liao JK
    Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
    Hollanders K; Van Bergen T; Kindt N; Castermans K; Leysen D; Vandewalle E; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1335-48. PubMed ID: 25626969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor.
    Kita T; Hata Y; Kano K; Miura M; Nakao S; Noda Y; Shimokawa H; Ishibashi T
    Diabetes; 2007 Jan; 56(1):231-8. PubMed ID: 17192487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.